0001127602-24-007627.txt : 20240229
0001127602-24-007627.hdr.sgml : 20240229
20240229163201
ACCESSION NUMBER: 0001127602-24-007627
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240227
FILED AS OF DATE: 20240229
DATE AS OF CHANGE: 20240229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoge Stephen
CENTRAL INDEX KEY: 0001760669
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 24704294
MAIL ADDRESS:
STREET 1: C/O MODERNA, INC.
STREET 2: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-02-27
0001682852
Moderna, Inc.
MRNA
0001760669
Hoge Stephen
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
President
0
Common Stock
1513433
D
Common Stock
4116
I
By Valhalla, LLC
Common Stock
151933
I
By Trust
Stock Option (Right to Buy)
96.20
2024-02-27
4
A
0
43894
0
A
2025-02-27
2034-02-27
Common Stock
43894
43894
D
Restricted Stock Units
0
2024-02-27
4
A
0
22987
0
A
Common Stock
22987
22987
D
These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
/s/ Brian Sandstrom, as Attorney-in-Fact
2024-02-29